82/100 A · Moderate risk
No major risk flags in public sources TraceComp due-diligence verdict — sanctions, screening, insolvency, control & financial signals combined.

✅ No sanctions, screening, insolvency or control red flags found in the public sources we cover. (Absence of a flag is not a guarantee — see methodology.)

NETRIS PHARMA

Active 5710 7211 Active for 17 years

5710 · RC 505014605 · Active since 2008

A

Overview

NETRIS PHARMA is a 5710 registered , France, since 2008. The company operates in the 7211 sector. With reported revenue of 322K EUR in 2023. Its TraceComp score of 82 (A) indicates solid fundamentals and low apparent risk. With 17 years of operations, the company has an established track record in its market.

Company Information

Registration Number
505014605
Legal Form
5710
Registered
2008-06-24

Financial Profile

Latest filed accounts: FY 2023 · most recent available in public filings

Revenue (2023) 322,052 EUR
Net Income -1,160,695 EUR
Total Assets 9,323,835 EUR
Altman Z 1.34 grey

Multi-year financials & ratios

3 years of filed accounts on file — full balance sheets, current ratio, debt-to-equity, net margin and the Altman-Z distress trend.

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Officers & Management

2 officers/directors on file — names, roles, appointment & resignation dates.

NameRoleStatus
JEAN-PIERRE BIZZARI role 73 Current
+ 1 more in the full report

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Research Output

Active research organization. 60 publications · 5,829 citations · h-index 47 in the global scholarly record (OpenAlex — 82.9M papers). Top fields by publication volume: Neuroscience (43%) · Biochemistry, Genetics and Molecular Biology (39%) · Medicine (19%).

See full research profile — top researchers & publications →

Source: OpenAlex (CC0). Objective publication & citation counts.

Patent Portfolio

Active patent holder. 4 patents · 4 active · 4 granted in the USPTO/EPO record.

See full patent portfolio — most-cited inventions & inventors →

Source: USPTO / EPO open patent data. Objective bibliographic counts.

Risk Signals

No adverse legal events have been recorded for this company.

  • Net loss reported in FY 2023

Data Sources & Freshness

Data sourced from: bulk register.